$91.18 Million in Sales Expected for Imperva Inc (IMPV) This Quarter
Wall Street brokerages expect Imperva Inc (NASDAQ:IMPV) to post sales of $91.18 million for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Imperva’s earnings, with the highest sales estimate coming in at $92.00 million and the lowest estimate coming in at $90.48 million. Imperva reported sales of $78.40 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.3%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, February 8th.
According to Zacks, analysts expect that Imperva will report full-year sales of $91.18 million for the current year, with estimates ranging from $321.00 million to $322.64 million. For the next year, analysts anticipate that the firm will post sales of $377.49 million per share, with estimates ranging from $372.00 million to $383.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Imperva.
Imperva (NASDAQ:IMPV) last announced its earnings results on Wednesday, November 8th. The software maker reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.11. The company had revenue of $83.89 million for the quarter, compared to analyst estimates of $83.79 million. Imperva had a negative return on equity of 8.52% and a net margin of 3.04%. The firm’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 earnings per share.
Several institutional investors have recently bought and sold shares of IMPV. SG Americas Securities LLC purchased a new stake in shares of Imperva during the third quarter worth $134,000. First Quadrant L P CA purchased a new stake in shares of Imperva during the third quarter worth $136,000. Ameritas Investment Partners Inc. increased its position in shares of Imperva by 18.7% during the second quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock worth $141,000 after acquiring an additional 464 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Imperva by 26.2% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock worth $201,000 after acquiring an additional 866 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of Imperva during the second quarter worth $206,000. 96.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of Imperva (IMPV) traded up $0.30 during midday trading on Monday, reaching $44.20. The company’s stock had a trading volume of 254,200 shares, compared to its average volume of 331,508. The stock has a market capitalization of $1,500.00, a price-to-earnings ratio of 163.70 and a beta of 1.78. Imperva has a 52 week low of $37.17 and a 52 week high of $52.40.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.